Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16551524rdf:typepubmed:Citationlld:pubmed
pubmed-article:16551524lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:16551524lifeskim:mentionsumls-concept:C0851346lld:lifeskim
pubmed-article:16551524lifeskim:mentionsumls-concept:C0725066lld:lifeskim
pubmed-article:16551524pubmed:issue1lld:pubmed
pubmed-article:16551524pubmed:dateCreated2006-3-22lld:pubmed
pubmed-article:16551524pubmed:abstractTextIn the era of image-guided radiation therapy (IGRT), the greatest challenge remains target delineation, as the opportunity to maximize cures while simultaneously decreasing radiation dose to the surrounding normal tissues is to be realized. Over the last 2 decades, technological advances in radiographic imaging, biochemistry, and molecular biology have played an increasing role in radiation treatment planning, delivery, and evaluation of response. Previously, fluoroscopy formed the basis of radiation treatment planning. Beginning in the late 1980s, computed tomography (CT) has become the basis for modern radiation treatment planning and delivery, coincident with the rise of 3-dimensional conformal radiation therapy (3DCRT). Additionally, multi-modality anatomic imaging registration was the solution pursued to augment delineation of tumors and surrounding structures on CT-based treatment planning. Although these imaging modalities provide the customary anatomic details necessary for radiation treatment planning, they have limitations, including difficulty with identification of small tumor deposits, tumor extension, and distinction from scar tissues. To overcome these limitations, PET and, more recently, PET-CT have been innovative regarding the extent of disease appraisal, target delineation in the treatment planning, and assessment of therapy response. We review the role of functional imaging in IGRT as it reassures transformations on the field of radiation oncology. As we move toward the era of IGRT, the use of multi-modality imaging fusion, and the introduction of more sensitive and specific PET-CT tracers may further assist target definition. Furthermore, the potential to predict early outcome or even detect early recurrence of tumor, may allow for the tailoring of intervention in cancer patients. The convergence of a biological target volume, and perhaps multi-tracer tumor, molecular, and genetic profile tumors will probably be vital in cancer treatment selection. Nevertheless, prospective clinical experience with outcome is encouraged and needs to be expanded to entirely exploit the benefits of the IGRT.lld:pubmed
pubmed-article:16551524pubmed:languageenglld:pubmed
pubmed-article:16551524pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16551524pubmed:citationSubsetIMlld:pubmed
pubmed-article:16551524pubmed:statusMEDLINElld:pubmed
pubmed-article:16551524pubmed:issn0958-3947lld:pubmed
pubmed-article:16551524pubmed:authorpubmed-author:SmithRyan PRPlld:pubmed
pubmed-article:16551524pubmed:authorpubmed-author:HeronDwight...lld:pubmed
pubmed-article:16551524pubmed:authorpubmed-author:AndradeRegian...lld:pubmed
pubmed-article:16551524pubmed:issnTypePrintlld:pubmed
pubmed-article:16551524pubmed:volume31lld:pubmed
pubmed-article:16551524pubmed:ownerNLMlld:pubmed
pubmed-article:16551524pubmed:authorsCompleteYlld:pubmed
pubmed-article:16551524pubmed:pagination3-11lld:pubmed
pubmed-article:16551524pubmed:meshHeadingpubmed-meshheading:16551524...lld:pubmed
pubmed-article:16551524pubmed:meshHeadingpubmed-meshheading:16551524...lld:pubmed
pubmed-article:16551524pubmed:meshHeadingpubmed-meshheading:16551524...lld:pubmed
pubmed-article:16551524pubmed:meshHeadingpubmed-meshheading:16551524...lld:pubmed
pubmed-article:16551524pubmed:meshHeadingpubmed-meshheading:16551524...lld:pubmed
pubmed-article:16551524pubmed:year2006lld:pubmed
pubmed-article:16551524pubmed:articleTitleAdvances in image-guided radiation therapy--the role of PET-CT.lld:pubmed
pubmed-article:16551524pubmed:affiliationDepartment of Radiation Oncology, University of Pittsburgh Cancer Institute, PA 15232, USA. heronD2@upmc.edulld:pubmed
pubmed-article:16551524pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16551524pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16551524lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16551524lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16551524lld:pubmed